Unlock this StockReport nowClick to Unlock

ValiRx Share Price

VAL 0.165p -0.0  -2.9%
19/07/19 150k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -51.8%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2018, ValiRx Plc revenues was not reported. Net loss increased 42% to £4.3M. Higher net loss reflects Administrative expenses increase of 48% to £2.2M (expense), Gain/Loss on Derivatives - Hedging increase from £23K to £442K (expense), Other operating income decrease from £89K (income) to £0K. Basic Earnings per Share excluding Extraordinary Items increased from -£0.02 to -£0.01. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for ValiRx
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Hardman & Company Martin Hall ,

Profile Summary

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Directors: Satu Vainikka (CEO) , Gerald Desler (CFO) , George Morris (COO) , Kevin Alexander (SEC) , Oliver de Giorgio-Miller (NEC) 61, Seppo Makinen (NED) 64,

No. of Employees: 12 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated January 26, 2000
Public Since February 28, 2000
Shares in Issue 1,024,057,953
Free Float 966.3m (94.4%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

VAL Share Price Performance VAL Share Price Quote
-0.0  -2.9%
Traded 3:33pm · Minimum 15 min delayed · NMS: 150k

Latest VAL News Announcements (delayed)

Upcoming VAL Events

Recent ↓
Friday 28th June, 2019
ValiRx PLC Annual Shareholders Meeting
Wednesday 29th May, 2019
Full Year 2018 ValiRx PLC Earnings Release
Friday 3rd May, 2019 (estimate)
Full Year 2018 ValiRx PLC Earnings Release
Tuesday 25th September, 2018
Half Year 2018 ValiRx PLC Earnings Release
Wednesday 30th May, 2018 (estimate)
ValiRx PLC Annual Shareholders Meeting
Friday 4th May, 2018 (estimate)
Full Year 2017 ValiRx PLC Earnings Release
Thursday 21st December, 2017
ValiRx PLC Ordinary Shareholders Meeting
Tuesday 26th September, 2017
Half Year 2017 ValiRx PLC Earnings Release
Tuesday 30th May, 2017
ValiRx PLC Annual Shareholders Meeting
Friday 5th May, 2017
Full Year 2016 ValiRx PLC Earnings Release
Tuesday 27th September, 2016
Half Year 2016 ValiRx PLC Earnings Release
Monday 20th June, 2016
ValiRx PLC Annual Shareholders Meeting
Thursday 19th May, 2016
Full Year 2015 ValiRx PLC Earnings Release
Monday 18th May, 2015
ValiRx PLC Reverse Split For VAL.L

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy VAL

Access VAL Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis